APG-115 in Combination With PD-1 Inhibitor in Patients With Advanced Liposarcoma or Advanced Solid Tumors
Status:
Recruiting
Trial end date:
2025-01-01
Target enrollment:
Participant gender:
Summary
Part 1 is a phase Ib standard "3 + 3" design, will be employed to determine the MTD of
APG-115 by assessing the DLT of APG-115 in combination with PD-1 inhibitor(toripalimab) in
advanced solid tumors.
Part 2 is a Simon two-stage phase II study design. At RP2D of APG-115 in combination with
toripalimab in advanced liposarcoma, approximately 34 patients will be treated with the
combination until disease progression, unacceptable toxicity, or another discontinuation
criterion is met.